168 related articles for article (PubMed ID: 37258608)
1. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T; Makiyama A; Shimokawa M; Otsuka T; Shinohara Y; Koga F; Ueda Y; Nakazawa J; Otsu S; Komori A; Arima S; Fukahori M; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Ureshino N; Mizuta T; Mitsugi K; Akashi K; Baba E
Sci Rep; 2023 May; 13(1):8815. PubMed ID: 37258608
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Yang L; Su J; Wang W; Zhou F
World J Surg Oncol; 2023 Jan; 21(1):19. PubMed ID: 36691032
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
4. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
5. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
[TBL] [Abstract][Full Text] [Related]
6. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
7. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
8. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
Hatashima A; Arango MJ; Reardon J; Freeman T; Williams T; McLaughlin EM; Abushahin L
Future Oncol; 2022 Jun; 18(20):2521-2532. PubMed ID: 35579260
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Hayuka K; Okuyama H; Murakami A; Okita Y; Nishiuchi T; Okano K; Suzuki Y; Tsuji A
Chemotherapy; 2021; 66(3):58-64. PubMed ID: 34284397
[TBL] [Abstract][Full Text] [Related]
11. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
12. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
[TBL] [Abstract][Full Text] [Related]
13. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
[TBL] [Abstract][Full Text] [Related]
14. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
Pijnappel EN; Dijksterhuis WPM; van der Geest LG; de Vos-Geelen J; de Groot JWB; Homs MYV; Creemers GJ; Mohammad NH; Besselink MG; van Laarhoven HWM; Wilmink JW;
J Natl Compr Canc Netw; 2021 Aug; 20(5):443-450.e3. PubMed ID: 34450595
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
[TBL] [Abstract][Full Text] [Related]
17. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Marschner N; Hegewisch-Becker S; Reiser M; von der Heyde E; Bertram M; Hollerbach SH; Kreher S; Wolf T; Binninger A; Chiabudini M; Kaiser-Osterhues A; Jänicke M;
Int J Cancer; 2023 Feb; 152(3):458-469. PubMed ID: 36053905
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Kang J; Hwang I; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Hong SM; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Aug; 36(4):732-741. PubMed ID: 29616439
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein/albumin ratio predicts survival after curative surgery in elderly patients with colorectal cancer.
Tamai K; Okamura S; Makino S; Yamamura N; Fukuchi N; Ebisui C; Inoue A; Yano M
Updates Surg; 2022 Feb; 74(1):153-162. PubMed ID: 33677820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]